Anondita Medicare Ltd, a Noida-based manufacturer of male and female condoms under the flagship brand “COBRA,” has opened its Initial Public Offering (IPO) for public subscription on August 22, 2025. The IPO, which will close on August 26, is already generating strong buzz in the grey market, where its shares are commanding a premium of ₹58 over the upper price band of ₹145. This signals investor optimism and hints at potential listing gains of up to 40% when the shares debut on NSE Emerge on September 1.
The IPO comprises a fresh issue of 47.93 lakh equity shares, with no offer-for-sale component. The company aims to raise ₹69.5 crore to fund capacity expansion, working capital needs, and future acquisitions.
🧭 IPO Details: Subscription Window and Financial Overview
| IPO Component | Details |
|---|---|
| Issue Type | SME IPO (Book Built) |
| IPO Open Date | August 22, 2025 |
| IPO Close Date | August 26, 2025 |
| Price Band | ₹137 – ₹145 per share |
| Lot Size | 1,000 shares |
| Minimum Investment | ₹2.74 lakh (2,000 shares at ₹137) |
| Total Issue Size | ₹69.5 crore |
| Listing Platform | NSE Emerge |
| Allotment Date | August 28, 2025 |
| Listing Date | September 1, 2025 |
Anchor investors have already committed ₹19.58 crore, adding further credibility to the offering.
📊 Grey Market Premium (GMP) and Listing Expectations
The grey market premium (GMP) for Anondita Medicare IPO surged from ₹28 on August 21 to ₹58 on August 22. This translates to an expected listing price of ₹200–₹205, significantly above the upper band of ₹145.
| Date | GMP (₹) | Expected Listing Price (₹) | Sentiment |
|---|---|---|---|
| August 20 | — | — | No activity |
| August 21 | ₹28 | ₹173 | Positive |
| August 22 | ₹58 | ₹203 | Strong demand |
The GMP trend reflects strong investor appetite, especially in the SME segment, where listing gains have historically been robust.
🔍 Company Profile: Anondita Medicare Ltd
Founded in March 2024, Anondita Medicare specializes in manufacturing flavored male condoms and has recently expanded into female condoms. The company operates 11 production lines in Noida, with an annual capacity of 562 million units.
| Product Category | Brand Name | Key Features |
|---|---|---|
| Male Condoms | COBRA | Flavored, electronically tested |
| Female Condoms | COBRA Femme | New product line, expanding reach |
| Flavors Offered | Strawberry, Mint, Chocolate, Butterscotch, Coffee, Bubblegum |
Anondita supplies to pharmaceutical companies, NGOs, and government health programs, and exports to Southeast Asia, Africa, and the Middle East.
🧠 Use of IPO Proceeds
The company has outlined a clear roadmap for deploying the ₹69.5 crore raised through the IPO:
| Allocation Purpose | Amount (₹ crore) | Strategic Impact |
|---|---|---|
| Equipment & Machinery Purchase | ₹6 | Capacity expansion |
| Working Capital Requirements | ₹35 | Operational liquidity |
| Future Acquisitions & Corporate Use | ₹28.5 | Growth and diversification |
This capital infusion is expected to enhance production efficiency and support Anondita’s expansion into new markets.
📉 Financial Performance and Valuation Metrics
Anondita Medicare has demonstrated strong financial growth over the past three years, with revenue and net income rising sharply.
| Fiscal Year | Revenue (₹ crore) | Net Income (₹ crore) | EBITDA Margin (%) | ROCE (%) | PE Ratio |
|---|---|---|---|---|---|
| FY2023 | ₹35.91 | ₹0.35 | 12.5 | 18.2 | — |
| FY2024 | ₹46.43 | ₹3.84 | 22.1 | 29.6 | — |
| FY2025 | ₹77.13 | ₹10.80 | 33.3 | 37.4 | 14.27–15.10 |
The company’s Return on Net Worth (RONW) stands at an impressive 41.71%, indicating strong profitability and efficient capital utilization.
🧠 Competitive Landscape: Cupid Ltd and Market Positioning
Anondita Medicare competes directly with Cupid Ltd, the only other listed player in India’s condom manufacturing segment. While Cupid has a longer track record, Anondita’s aggressive expansion, flavor innovation, and export strategy give it a competitive edge.
| Company Name | Market Segment | Key Differentiator |
|---|---|---|
| Anondita Medicare | Male & Female Condoms | Flavor range, export focus |
| Cupid Ltd | Female Condoms | Established brand, niche focus |
The IPO offers investors a chance to participate in a fast-growing, underpenetrated market with strong public health relevance.
🧠 ESG and Sustainability Practices
Anondita Medicare has adopted eco-friendly manufacturing practices, including the use of CNG as fuel and recyclable packaging. The company also partners with NGOs and government programs to promote family planning and sexual health awareness.
| ESG Initiative | Description |
|---|---|
| Green Manufacturing | CNG-powered production lines |
| Social Impact Partnerships | Collaborations with NGOs and health bodies |
| Employee Strength | 280 (as of July 2025) |
These initiatives enhance the company’s brand equity and align with global sustainability goals.
📌 Conclusion
Anondita Medicare’s IPO debut on August 22 marks a significant milestone for India’s sexual wellness industry. With a ₹69.5 crore raise, strong grey market premium, and robust financials, the company is well-positioned for both short-term listing gains and long-term growth.
As demand for affordable, quality contraceptives rises globally, Anondita’s strategic focus on innovation, exports, and public health partnerships makes it a compelling investment opportunity. Investors should, however, assess risk factors and consult financial advisors before subscribing.
—
Disclaimer: This article is based on publicly available IPO documents and media reports as of August 22, 2025. It is intended for informational purposes only and does not constitute investment advice. Please consult a certified financial advisor before making any investment decisions.
